Applying the healing properties of progenitor cell therapies to alleviate and heal a range of medical conditions – starting with dermatology and gynecology.
Elanix develops and markets progenitor cell-based products to help regenerate tissue and promote healing in the treatment of burns, and gynecological and dermatological conditions. The Company is headquartered in Nyon, Canton Vaud, Switzerland, with offices in Potsdam, Germany, and listed on the Frankfurt stock exchange under the symbol ELN.
Progenitor cells are fully differentiated yet immunologically neutral cells that are very potent inducers of tissue growth and healing. Elanix enhances the activity of progenitor cells with proprietary cytokine formulations to create unique cell therapy products and procedures.
MARKETED PRODUCTS & PIPELINE
Elanix owns two cosmetic creams, GYNrepair® and RepAir-A N, marketed in Switzerland since 2011 in gynecology and dermatology.
Elanix is developing a bioresorbable & bioactive skin dressing derived from progenitor skin fibroblasts to accelerate regeneration and improve quality of skin following acute burns.
Financial information and stock performance data can be found in the Investor Relations sections in both English and German
Elanix Acquires Third Cell Based Bioactive Cream Formulation with Potential to Alleviate a Significant Chronic Dermatological Conditionview article
Elanix Biotechnologies AG: CEO informs about planned cash capital increase with indirect subscription rights
Elanix Biotechnologies AG: CEO informs about pl [...]view article
Elanix Biotechnologies AG announces non-binding letter of intent with Oxford MEStar Ltd. in regard to setting up a JV to market GynRepair in China
Potsdam, November 22, 2016 – Elanix Biote [...]view article
ELANIX BIOTECHNOLOGIES AG STRATEGIC PARTNER, TRANSWELL BIOTECHNOLOGY LTD., RECEIVES US FDA CLEARANCE FOR PHASE I/II CLINICAL TRIAL USING FIBROBLAST PROGENITORS TWB-103
Nyon, Switzerland and Potsdam, Germ [...]view article